Nanjing CoreTech biomedical Co,.Ltd., established in 2002, is a institute of the bioengineering and pharmaceutical industry controlled by Nanjing New Industrial Investment Group for the purpose of industrialization. We have two core businesses: research and industrialization of APIs and intermediates, biomedical research and R & D outsourcing.

In the part of APIs and intermediates, our company has successfully developed more than 120 new drug technologies, of which 70 products can be provided to customers at home and abroad stably. The quality of our products all meets international standards, like EP, USP-NF and etc.

The R & D and incubation center of the company covers 26,000 square meters. It has built and completed the platform of R&D, life science technology and CMO. Led by a number of PhDs and overseas high-level talent, the medical R & D and life science professional and technical team specialize in new drug discovery, research, registration, clinical CRO and so on and they are able to provide more than 500 professional and technical services for biomedical related fields. 

In recent years, the company has been enriching the abilities of transnational technology transfer, Industry-University-Research collaboration, high-level talent innovation and entrepreneurship and R & D outsourcing resources. For example, we have carried out industry-university-research cooperation with Academician Zhang Yaoming of Southeast University and Academician Chen Hongyuan of Nanjing University, and established strategic cooperative relations with British Cels, British Technology links2, American XBL, Xiansheng Pharmaceutical, Yangzijiang Pharmaceutical and other enterprises.